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Background
Presumptive treatment for malaria is common in
resource-limited settings, yet controversial given the
imprecision of clinical diagnosis. We compared costs of
diagnosis and drugs for two strategies: (1) empirical
treatment of malaria via clinical diagnosis; and (2)
empirical diagnosis followed by treatment only with
Giemsa smear confirmation.
Materials and methods
Patients with a diagnosis of clinical malaria were
recruited from a medical center in southwestern Nigeria.
The patients received free Giemsa thick (diagnosis) and
thin (differentiation) smears, but paid for any antimalarial
treatment. Clinical diagnosis was made on clinicians’
judgments based on symptoms, including fever, diarrhea,
headache, and body-aches. The pediatric regimen was
artesunate (6-9 tablets of 3mg/ kg on day one and 1.5mg/
kg for the next four days) plus amodiaquine (10mg/kg
day 1-2 and 5mg/kg on day three in suspension). Adults
were given two treatment options: option one (4.5 50mg
artesunate tablets on day one and nine for the next four
days, plus three 500mg sulfadoxine/25 mg pyrimetha-
mine tablets) and option two (4.5 50mg artesunate tablets
on day one and nine for the next four days plus nine
200mg tablets of amodiaquine at a dose of 10mg/kg day
1-2 and 5mg/kg on day three). We calculated the costs of
smears/drugs from standard medical center charges.
Results
Doctors diagnosed 304 patients (170 adults ages ≥16 years
and 134 pediatric) with clinical malaria, prescribing
antimalarial drugs to all. Giemsa thick smears were posi-
tive in 115/304 (38%). The typical patient cost for a
Giemsa smear was 550 Naira (US$3.74 in 2009). For chil-
dren, the cost of testing all, but treating only Giemsa posi-
tives was N888($6.04)/child; cost of empiric treatment of
all who were clinically diagnosed was lower, N660($4.49)/
child. For adults, the cost of testing all, but treating only
Giemsa positives was N711($4.84)/adult for treatment
option one (artesunate and sulfadoxine/ pyrimethamine)
and N730($4.97)/adult for option two (artesunate and
amodiaquine). This contrasts to lower costs of empiric
treatment for both options one (N610=$4.14/adult) and
two (N680=$4.63/adult).
Conclusions
The most cost-effective approach to malarial manage-
ment was empiric treatment, though many uninfected
Nigerians will receive antimalarial drugs. If diagnostic
costs declined, the cost-effectiveness calculus would
change accordingly.
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